Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

10 treatments under study, led by Laboratory Biomarker Analysis

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (3)
Phase 2 (1)

Trial Status

Completed3
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT03147768Phase 1Completed

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

NCT00454363Phase 2Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT02831179Phase 1Withdrawn

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

NCT01204476Phase 1Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Showing all 4 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis3
  • Pharmacological Study3
  • Veliparib1
  • Everolimus1
  • Temozolomide1

Active Sponsors

  • National Cancer Institute (NCI)4
  • Vanderbilt-Ingram Cancer Center1
  • CHI St. Luke's Health, Texas1
  • Laser Tissue Welding, Inc.1

Top Investigators

Related Conditions

  • Pancreatic Polypeptide Tumor3
  • Pancreatic Insulinoma3
  • Somatostatinproducing Neuroendocrine Tumor3
  • Recurrent Pancreatic Neuroendocrine Carcinoma2
  • Metastatic Digestive System Neuroendocrine Tumor G12

Activity Timeline